Prevention and Control of Seasonal Influenza with Vaccines Recommendations of the Advisory Committee on Immunization Practices - United States, 2016-17 Influenza Season
Prevention and Control of Seasonal Influenza with Vaccines Recommendations of the Advisory Committee on Immunization Practices - United States, 2016-17 Influenza Season
复制标题
DOI：
10.15585/mmwr.rr6505a1
复制
发表时间：
2016-08-26
影响因子：
33.7
通讯作者：
Bresee, Joseph S.
中科院分区：
文献类型：
--
作者：
Grohskopf, Lisa A.;Sokolow, Leslie Z.;Bresee, Joseph S.
本报告更新了免疫实践咨询委员会(ACIP)2015-16年度关于使用季节性流感疫苗(Grohskopf LA、Sokolow LZ、Olsen SJ、Bresee JS、Broder KR、Karron RA)的建议。用疫苗预防和控制流感：免疫做法咨询委员会的建议，美国，2015-16年流感季节。MMWR MORB人类Wkly代表2015；：818-25)。建议所有月龄大而无禁忌症的人士每年接种一次流感疫苗。在2016-17年流感季节，灭活流感疫苗(IIV)将有三价(IIV3)和四价(IIV4)配方可供选择。重组流感疫苗(RIV)将以三价制剂(RIV3)上市。鉴于美国在2013-14年度和2015-16年度对甲型H1N1流感pdm09的防效较低，对于2016-17年度的流感季节，ACIP提出了不应使用减毒活流感疫苗(LAIV4)的临时建议。2016-17年度美国三价流感疫苗中包括的疫苗毒株将是类似A/California/7/2009(H1N1)的病毒、类似A/Hong Kong/4801/2014(H3N2)的病毒和类似B/Brisbane/60/2008的病毒(维多利亚谱系)。四价疫苗将包括一种额外的B型流感病毒株，一种类似B/Phuket/3073/2013的病毒(Yamagata谱系)。讨论了使用不同疫苗类型和特定人群的建议。应该使用获得许可的、与年龄相适应的疫苗。对于有超过一种许可的推荐产品的人，不会优先推荐一种流感疫苗产品而不是另一种。本信息面向疫苗接种提供者、免疫规划人员和公共卫生人员。本报告中的信息反映了ACIP在2015年10月21日、2016年2月24日和2016年6月22日举行的公开会议上的讨论。这些建议适用于食品和药物管理局许可适应症内使用的所有许可流感疫苗，包括在本报告发表后获得许可的疫苗。有关最新情况和其他信息，请访问疾控中心的流感网站(http://www.cdc.govfflit).疫苗接种和医疗保健提供者应定期查看疾控中心的流感网站，了解更多信息。
This report updates the 2015-16 recommendations ofthe Advisoiy Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines (Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 influenza season. MMWR Morb Mortal Wkly Rep 2015;64:818-25). Routine annual influenza vaccination is recommended for all persons aged months who do not have contraindications. For the 2016-17 influenza season, inactivated influenza vaccines (IIVs) will be available in both trivalent (IIV3) and quadrivalent (IIV4) formulations. Recombinant influenza vaccine (RIV) will be available in a trivalent formulation (RIV3). In light of concerns regarding low effectiveness against influenza A(H1N1)pdm09 in the United States during the 2013-14 and 2015-16 seasons, for the 2016-17 season, ACIP makes the interim recommendation that live attenuated influenza vaccine (LAIV4) should not be used. Vaccine virus strains included in the 2016-17 U.S. trivalent influenza vaccines will be an A/California/7/2009 (H1N1) like virus, an A/Hong Kong/4801/2014 (H3N2) like virus, and a B/Brisbane/60/2008 like virus (Victoria lineage). Quadrivalent vaccines will include an additional influenza B virus strain, a B/Phuket/3073/2013 like virus (Yamagata lineage).Recommendations for use of different vaccine types and specific populations are discussed. A licensed, age -appropriate vaccine should be used. No preferential recommendation is made for one influenza vaccine product over another for persons for whom more than one licensed, recommended product is otherwise appropriate. This information is intended for vaccination providers, immunization program personnel, and public health personnel. Information in this report reflects discussions during public meetings ofACIP held on October 21, 2015; February 24, 2016; andJune 22, 2016 These recommendations apply to all licensed influenza vaccines used within Food and DrugAdministration licensed indications, including those licensed after the publication of this report. Updates and other information are available at CDC's influenza website (http://www.cdc.govfflit). Vaccination and health care providers should check CDC's influenza website periodically for additional information.